HC Wainwright Issues Positive Forecast for IceCure Medical (NASDAQ:ICCM) Stock Price

IceCure Medical (NASDAQ:ICCM) had its price target upped by HC Wainwright from $2.00 to $2.50 in a research report report published on Tuesday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also weighed in on ICCM. Brookline Capital Management restated a “buy” rating on shares of IceCure Medical in a research note on Wednesday, August 13th. Zacks Research lowered IceCure Medical from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Wall Street Zen lowered IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Loop Capital set a $2.77 price target on IceCure Medical in a research note on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research note on Saturday, September 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $2.64.

IceCure Medical Price Performance

ICCM opened at $1.00 on Tuesday. The business’s 50-day moving average is $0.98 and its two-hundred day moving average is $1.04. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.18 and a quick ratio of 0.88. The firm has a market capitalization of $68.69 million, a PE ratio of -6.25 and a beta of 0.31.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.12. IceCure Medical had a negative return on equity of 136.96% and a negative net margin of 317.62%.The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $0.90 million. Research analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.